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Pendahuluan:  Kanser tiroid jenis diferensiasi atau dibezakan: Perubahan pada 
keputusan pemeriksaan fungsi peparu selepas menerima rawatan pertama radioaktif iodin. 
 
Pengenalan: Penyakit tiroid boleh dibahagikan kepada jenis yang merbahaya seperti 
kanser dan juga tidak merbahaya. Rawatan bagi penyakit tiroid telah lama dipraktikkan 
berdasarkan garis panduan yang dikeluarkan oleh Persatuan Tiroid Amerika. Radioaktif 
iodin atau Iodin-131 digunakan sebagai rawatan untuk kanser tiroid dan penyakit 
hipertiroidisma(kadar hormon tiroid yang tinggi). Keradangan peparu dan fibrosis peparu 
ialah antara komplikasi yang dialami oleh pesakit yang menerima rawatan iodin-131. 
Pesakit kanser tiroid jenis dibezakan mempunyai jangka hayat yang lebih lama berbanding 
pesakit kanser yang lain walaupun kanser telah merebak jauh ke organ lain. Oleh itu, 
peparu yang berfungsi dengan baik adalah penting untuk kelangsungan hidup dan kualiti 
hidup. Kajian terbaru ke atas pesakit yang mempunyai kanser tiroid yang merebak ke 
peparu mendapati bahawa fungsi peparu berkurangan semasa lawatan susulan.  
 
Objektif: Tujuan penyelidikan adalah untuk menilai perubahan fungsi peparu dalam 
pesakit kanser tiroid selepas terdedah kepada rawatan iodin-131 yang pertama dan untuk 
mencari perbezaan fungsi peparu antara pesakit dengan atau tanpa merebak ke peparu. 
 
Kaedah: Pesakit kanser tiroid yang telah melakukan pembedahan pembuangan tiroid 
dan dirujuk untuk rawatan iodin-131 dinilai dan diambil sebagai peserta kajian. Pesakit ini 




iodin-131. Pemeriksaan fungsi peparu yang kedua dan ketiga dilakukan 3 dan 6 bulan 
selepas rawatan diberikan. Data klinikal dianalisa menggunakan perisian IBM SPSS.  
 
Keputusan: Seramai 49 peserta dengan median dan min berumur lingkungan 40 tahun 
telah terlibat dan kebanyakannya terdiri daripada wanita (88%). 65% terdiri daripada kaum 
Melayu. Lapan pesakit menghidapi kanser yang telah merebak ke peparu. 2 daripadanya 
dikesan melalui skan pengimejan tomografi berkomputer sebelum menerima rawatan iodin-
131, manakala selebihnya melalui skan seluruh badan iodin-131. 24 peserta mempunyai 
bacaan awal fungsi peparu yang normal. Median bacaan asas fungsi peparu bagi kapasiti 
vital paksa (FVC)=79%, isipadu hembusan paksa dalam 1 saat (FEV1)=84% dan 
FEV1/FVC=88. Tiada perubahan yang signifikan bagi bacaan FVC, FEV1 dan FEV1/FVC, 
3 dan 6 bulan selepas rawatan iodin-131 (p=0.985, p=1.0 dan p=0.58 masing-masing). 
Tiada perubahan  fungsi peparu yang signifikan juga bagi pesakit yang mempunyai bacaan 
asas yang normal atau tidak normal dan juga untuk pesakit yang merebak ke peparu atau 
tidak. 
 
Kesimpulan: Tiada kemerosotan pada fungsi peparu yang signifikan selepas menerima 
rawatan pertama iodin -131 walaupun di kalangan pesakit bacaan asas yang tidak normal 
atau pesakit kanser yang merebak ke peparu 
 
Perkataan Utama: Kanser tiroid, Perubatan Nuklear, Pengimejan Radionuklid, Rawatan 







Title: Differentiated Thyroid Cancer: Changes in The Pulmonary Function Test 
Post First Radioactive Iodine Treatment  
 
Introduction: A thyroid disease could be benign or malignant. Management of thyroid 
disease has been well established and documented following the American Thyroid 
Association Guidelines. Radioactive Iodine (RAI) or Iodine-131 (131I) is used to treat 
differentiated thyroid cancer and benign hyperthyroidism. Radiation pneumonitis and lung 
fibrosis are lungs complication beside other complication after the exposure of Iodine-131. 
Differentiated Thyroid Cancer (DTC) patients have longer survival rate as compared to 
other solid tumour even if the patients had distant metastasis at first diagnosis.  Thus, 
having good lung function is essential for the survival and quality of life. Recent study 
showed that lung function of some patients with lung metastasis has been found severely 
impaired during follow-ups. 
 
Objective: The aim is to evaluate changes of pulmonary function in DTC patients after 
exposure to first Iodine-131 treatment and to look for differences between patients with or 
without lung metastasis 
 
Methods: Post total or near total thyroidectomy differentiated thyroid cancer patients 
referred for first Iodine-131 treatment were evaluated and recruited as study subjects. These 




Repeated PFT was performed at 3 and 6 months after the first Iodine-131 treatment. 
Clinical data was analysed using IBMM SPSS software. 
 
Results: A total of 49 patients with the median and mean age of 40’s were recruited 
and the majority were females (88%) and by ethnicity, the majority were Malay which was 
about 65%. 8 patients had metastasis whereby 2 were diagnosed based on computed 
tomography (CT) findings during pre- Iodine-131 ablation and the rest based on post 
Iodine-131 treatment whole body scan. 24 patients had normal baseline PFT. The median 
value of baseline PFT was forced vital capacity (FVC)=79%, forced expiratory volume in 1 
second (FEV1)=84% and FEV1/FVC=88. There were no significant changes of FVC, 
FEV1 and FEV1/FVC after 3 and 6 months of Iodine-131 ablation (p=0.985, p=1.0 and 
p=0.58 respectively). There were also no significant changes of PFT for patients with 
normal or abnormal baseline as well as for patients with or without lung metastasis.  
 
Conclusion: There was no significant worsening of pulmonary function test in the 
differentiated thyroid cancer patients after their first radioactive iodine treatment even for 
patients with abnormal baseline or patients with lung metastasis. 
 
Keyword: Thyroid cancer, Nuclear Medicine, Radionuclide imaging, Radioactive 





1.0 INTRODUCTION & LITERATURE REVIEW 
1.1 Thyroid Cancer 
 Definition and Demographics  1.1.1
	
 Thyroid cancer is known as the most common malignancy of endocrine but it only 
accounts for 1% of malignancy of all tumours. The incidence of thyroid cancer is on the 
rise over the years due to public awareness and advancement of imaging modalities on 
detecting thyroid cancer including microcarcinoma of the thyroid. Microcarcinoma is 
referring to a tumour, which is of less than 1cm in longest diameter (Ziessman et al, 
Haugen et al). There were 2 million patients globally diagnosed with thyroid cancer in 
2015 (Murtaza Mustafa, 2017). 
 The incidence of thyroid cancer was higher in goitre prevalence community, a 
benign condition of thyroid disease. Locally, 7 states in Malaysia have been identified by 
MOH as an endemic area of goitre. Thyroid cancer was listed in top 5 cancers in the 
endemic states of goitre like Sabah and Kelantan, while it was not even listed in top 10 
cancers in Penang, as it was a non-endemic state of goitre. (Othman N.H. et al, 2018). 
Another study done by Othman N.H. et al (2009) in Kelantan from year 1994 to 2004, 
about 60% of thyroid cancer patients also have background of prolonged goitre. 
 According to the latest local data from the MALAYSIAN NATIONAL CANCER 
REGISTRY REPORT 2007 – 2011, by National Cancer Institute, there were 103,507 new 
cancer cases reported in Malaysia. Thyroid cancer was the 9th commonest cancer among 
Malaysian women since 2007 until 2011, which was about 3% of all types. In the age group 
of 15-24 years old for both genders, thyroid cancer was the 4th commonest, which was 
about 10.7%.  The highest incidence rate within ethnicity was Malays in both males and 
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females. Among Malay women, thyroid cancer ranked 8th, about 4.2% and among women 
of other ethnic groups, it ranked 10th which was 3.7% of all cancer. However, thyroid 
cancer was less common among Malaysian males generally and it was ranked 17th. In 
summary, the risk of thyroid cancer was 1 in 336 for women and 1 in 284 among Malay 
women while it was 1 in 884 for men and 1 in 734 among Malay men. 48% of male 
patients and 60% of female patients were diagnosed with stage I and II (Azizah Ab M, 
2015). From Malaysia Cancer Incidence in Peninsular Malaysia 2002 – 2005, the male to 
female ratio was approximately 1:3 and this was comparable to that of the US and 
Singapore (Lim G.C.C. et al, 2008).  
 Thyroid cancer arises from follicular C-cell but some rare cancer arises from other 
cells such as lymphoma, sarcoma and hemangiosarcoma. Types of cancer are based on 
histological features that are papillary, follicular, medullary and anaplastic (Elisei et al, 
2013).  Papillary and follicular thyroid cancer arise from thyroid follicular cells and are 
defined as differentiated thyroid cancer (DTC) (Ziessman et al, 2014). DTC maintains its 
normal features of follicular cells hence maintain the ability to take up iodine and produce 
thyroglobulin. In most cases, papillary thyroid cancer (PTC) is the commonest histology, 
which accounts for 80% of all thyroid cancer followed by follicular thyroid cancer (FTC), 
at 10%. The most diagnosed Thyroid Cancer is the small PTC with an indolent clinical 
course (M.J. Jeon, 2018). The DTC normal feature also results in having good response 
towards RAI treatment, which subsequently leads to excellent prognosis and high survival 






 Clinical Presentation and Risk Factor 1.1.2
 
 Clinically, the most common presentation of thyroid cancer is asymptomatic thyroid 
nodule or mass that can be felt in the neck. The nodule can be either single or multiple 
which is usually fixed and firm in consistency. Some nodule could rapidly increase in size 
over weeks or months. Study done by Abdullah et al (2002) in Kuala Lumpur found that 
single nodule variation was the main mode of presentation which accounts about 70% of 
the total cases, followed by generalised thyroid enlargement (19%) and cervical lymph 
node enlargement alone (5.6%).  
The differentiation between benign and tumour is very important for the patients as 
it will lead to different overall management methods altogether. Some patients have 
obstructive features like dysphagia, difficulty of breathing and persistent cough as well as 
changes of voice due to involvement of laryngeal nerve and vocal cord palsy (Elisei et al, 
2013). In some rare cases, patient would present with distant metastatic symptoms like 
bone pain and lymph nodes enlargement. A study done by Sothy K. (1991) in Kelantan 
established that there were 20% of patients presented with obstructive symptoms, 19% with 
bone metastases and 12% had cervical lymph node. Usually patients are euthyroid but 
patient with large or metastatic disease may present with hyperthyroidism or 
hypothyroidism (Murtaza M. et al, 2017). 
 Majority of patients (93.5%) had multinodular goitre prior to cancer (Sothy K. et al, 
1991). Genetic predisposing factor and environmental are thought to be the risk factor of 
thyroid cancer (Murtaza M. et al, 2017, Ziessman et al 2014). First-degree relatives of 
thyroid cancer patients have 5.4 fold-increased risk of getting it followed by 2.2 and 1.8 
fold for second and third-degree relatives (Oakley et al, 2013). Direct or indirect exposure 
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to ionising radiation increased the risk from 15 to 53 fold of getting DTC (Hancock et al, 
1995). Several thousands of thyroid cancer cases were diagnosed among those who had 
been exposed to Iodine-131 from the nuclear reactor accident in Wind scale, Britain, 
Chernobyl, Soviet Union and Fukushima, Japan (McNally et al, 2016). Hence a complete 
medical history is crucial. Physical examination is also equally important e.g. examination 
of the neck to look for thyroid or nodule’s characteristic, lymph node’s involvement, 
obstructive features and extent of the disease (Elisei et al, 2013). However, obesity is still 




 Ultrasound is a commonly used imaging method to detect the presence and 
characteristic of thyroid nodule as well as status of the whole thyroid gland (Murtaza M. et 
al, 2017; Haugen et al, 2016). It helps in measuring the size, number and extension of the 
nodule. Patterns of high suspicion of the nodule on ultrasound are solid hypoechoic or 
partially cystic, irregular margin or calcified margin with small extrusive soft tissue, 
microcalcification, taller than wide and evidence of extrathyroidal extension (ETE). The 
estimated risk of malignancy is between 70 to 90% (American Thyroid Association (ATA) 
Management Guidelines for Adult Patients with Thyroid Nodule and Differentiated 
Thyroid Cancer by Haugen B.R. et al, 2015). 
 Fine needle aspiration cytology (FNAC) is usually performed following the 
ultrasound finding. It is also best done under ultrasound guided to reduce the incidence of 
false negative result by locating the nodule. The cytology finding should be reported base 
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on the Bethesda System provided by 2007 National Cancer Institute Thyroid Fine-Needle 
Aspiration State of the Science Conference (Haugen B.R. et al, 2015).   
 
 Staging  1.1.4
	
 Thyroid cancer stage follows the American Joint Committee against Cancer 
(AJCC)/Union for International Cancer Control (UICC) TNM system, which refers to the 
size or extent of the tumour histopathologically (T), any lymph node spread (N) and distant 
metastasis (M), as shown in Table 1.1. Staging is required for cancer registries and 
predicting disease mortality.  
From 2nd until 7th edition of AJCC, the age of cut-off for staging is 45 years old. 
Multiple studies have been done and recommended that the age cut-off needed to be 
increased to 55 years or using multiple age categories to have better reflection of 
relationship between age and prognosis (Yoon Lee et al, 2017). A total of 9484 patients 
from 10 different international institutions were included in a study done by Nixon et al in 
2016 to validate the 55 years old as a cut-off for risk stratification. They found that the 10-
year disease-specific survival (DSS) for stage I-IV were 99.7%, 97.3%, 96.6% and 76.3%, 
respectively, when using 45 years as a cut-off age. While the 10-year DSS for stage I-IV 
were 99.5%, 94.7%, 94.1% and 67.6%, respectively, when using 55 years as a cut-off age. 
Change in the cut-off age lead to downstaging of 12% of patients and the downstaged 
group had a 10-year DSS of 97.6%. This prevents overstaging of patients with low risk 




Updated version of 8th AJCC system was announced in mid-2016 and was effective 
in January 2018. The age of cut-off for staging is increased from 45 to 55 years at 
diagnosis.  
Table 1.1: AJCC/UICC TNM Staging for Differentiated Thyroid Cancer 8th Edition, 
published in Head and Neck Pathology, Volume 12, Issue 3, September 2018 by Springer. 




I Any size of tumour, located in the thyroid with or without lymph 
nodes or tissue 
II Any size of tumour with distant metastasis 
55 and 
above 
I Tumour no larger than 4cm and confined to the thyroid  
II - Tumour of any size with nearby lymph node involvement 
- Tumour that has grown into the strap muscles around the thyroid with 
or without lymph node involvement 
III Tumour has grown extensively into nearby tissues: larynx, trachea, 
oesophagus or laryngeal nerve with or without lymph node 
IVA Tumour has grown extensively back toward the spine or into nearby 
large vessels with or without lymph node 
IVB Tumour of any size with or without lymph node and has distant 




The ATA guideline further divides patients with DTC into high, intermediate and 
low risk categories depending on histopathological examination (HPE), lymph node 
involvement, distant metastasis, Serum thyroglobulin (Tg) and RAI whole body scan 
(WBS) findings (Table 1.2). Patient will be treated according to their risk.  
Table 1.2: ATA 2009 Risk Stratification System with Proposed Modification 
LOW RISK Papillary thyroid cancer: 
a) No metastases: local or distant 
b) All macroscopic tumour has been resected 
c) No tumour invasion of loco-regional tissue or structures 
d) The tumour does not have aggressive histology 
e) If 131I therapy is given, there are no RAI-avid metastatic foci 
outside the thyroid bed on the first posttreatment WBS. 
f) No vascular invasion 
g) Clinical N0 or ≤5 pathologic N1 micrometastases(<0.2cm) 
Intrathyroidal, encapsulated follicular variant of PTC 
Intrathyroidal, well differentiated FTC with capsular invasion and 
no or minimal (<4 foci) vascular invasion. 
Intrathyroidal, papillary microcarcinoma (mPTC), unifocal or 
multifocal, including BRAFV600E mutated (if known) 
INTERMEDI
ATE RISK 
Microscopic invasion of tumour into the perithyroidal soft tissues 
RAI-avid metastatic foci in the neck on the first posttreatment WBS 




PTC with vascular invasion 
Clinical N1 or >5 pathologic N1 (all involved lymph nodes <3cm) 
Multifocal mPTC with ETE and BRAFV600E mutated 
HIGH RISK Macroscopic invasion of tumour into the perithyroidal soft tissue 
(gross ETE) 
Incomplete tumour resection 
Distant metastases 
Postoperative serum Tg suggestive of distant metastases 
Pathologic N1 with any metastatic lymph node ≥3cm 
FTC with extensive vascular invasion (>4 foci) 
 
 Distant Metastasis 1.1.5
	
 Distant metastasis of thyroid cancer, which is uncommon in DTC patients, with a 
wide range of prevalence (4-23%) has been reported and often viewed as life threatening 
(Song H.J. et al, 2015). The majority of deaths among thyroid cancer patients were indeed 
of those patients with distant metastatic disease. Long-term survival rate also has a wide 
range from 13 to 100% due to heterogeneity in patients (Kim H et al, 2018). They have 
varying clinical outcomes from complete remission to rapidly progression and death (Song 
H.J. et al, 2015). In high risk patients especially those presented with extrathyroidal 




 Lungs are the most common sites of distant metastasis. Diagnosis of lung 
metastases was based on clinical, preoperative or postoperative chest CT findings or post 
therapeutics RAI-131 ablation whole-body scans (Song H.J., 2015). Study done by Kim H. 
et al (2018) found that at initial presentation, 62% patient had only lung metastasis, 20% 
had only bone metastasis and 18% had combined lungs and bone metastasis. About 50% of 
patients with lung metastases died within 10 years and respiratory failure were the most 
common cause of death (Song H. J. et al, 2015). FTC has poorer prognosis compared to 
that of PTC (Jeon M. et al, 2018). Therefore, more aggressive and repeated RAI-131 
therapies are given to the patients with lung metastases as long as iodine avidity is presence 




For about seven decades, thyroid cancer patients who are proven by biopsy have 
been recommended for surgical thyroidectomy, remnant RAI-131 ablation and followed by 
thyroid hormone suppression therapy (Kwong N. et al, 2014). The initial treatment for 
patients with thyroid cancer with the size of at least 1cm is to remove the primary tumour 
with the affected thyroid lobe by undergoing total or near total thyroidectomy. Therapeutic 
lymph node dissection would be performed on patient whose lymph node involvement is 
evident clinically on ultrasound and lymph node Fine Needle Aspiration Cytology (FNAC). 
This may reduce the risk of recurrence and to enable the RAI therapy (Haugen B.R. et al, 




The remnant RAI ablation is an attempt to destroy any residual normal thyroid 
tissue or known macroscopic thyroid cancer post-surgery.  A high-risk patient will receive 
remnant RAI ablation following surgery while it is not necessary for a low-risk patient.  
RAI may be indicated for an intermediate risk patient.  
Removal of thyroid gland in a patient will also cause drop of thyroid hormone (T4 
and T3) level and cause rising of his/her thyroid stimulating hormone (TSH) level. The 
increased TSH may promote growth of any potential residual tumour cells. By giving 
thyroid hormone replacement therapy (levothyroxine) to the patient, it can suppress the 
TSH level.  The patient must be supplied with this thyroid hormone replacement therapy 
for the rest of his/her life.  
Serum Tg should be undetectable post total thyroidectomy. Presence of serum Tg 
level may indicate presence of residual or recurrence thyroid cancer cell. Thus monitoring 
of serum Tg as a tumour marker is crucial (Haugen B.R. et al, 2015, F. Pacini et al 2002).  
 Based on post RAI ablation whole body scan, the lung metastases were classified 
into iodine avid and non iodine avid. The iodine avid has functioning lung metastasis while 
the non iodine avid has non functioning lung metastasis. The benefit of radioiodine ablation 
is very limited for non iodine avid lung metastases (Song H.J., 2015). 70% of patients with 
lung metastases are iodine avid. Several studies found that patients with iodine avid lung 
metastases had longer survival rates compared to the non iodine avid lung metastatic 
patients. Iodine avid DTC patients with lung metastasis have longer survival rates than 
those with non iodine avid metastasis, 60% and 10%, respectively (Jang E.K et al, 2015). 
Most iodine avid lung metastasis DTC patients obtained partial or complete remission 
about 60% and 24%, respectively, with significant decrease of serum Tg level. They also 
had reduction in pulmonary metastases on follow up CT (Song H. J. et al, 2015). 
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1.2 Radioiodine (RAI) Therapy 
 
 Radioiodine (RAI) or Iodine-131 (131I) was first introduced as an oncologic 
therapeutic agent in the early 1940s. And now after 80 years, Iodine-131 is available in 
many centres and has become the main mode of treatment. 
 Iodine-131 is formed from fission of uranium and can be produced in a reactor. It 
then decays into Xe-131 by emitting Beta (β) and Gamma (γ) rays. The β-ray has maximum 
energy of 0.61MeV (89% abundance) with an average energy of 0.192MeV. The β-ray will 
be emitted into the soft tissue with mean range of 0.4mm and can go up to 0.8mm in the 
tissue (Mumtaz M. et al, 2009). This high energy of β-ray is not for imaging but is valuable 
for therapy (Lin et al, 2015). Meanwhile, the γ-ray has 0.364MeV (81% abundance) and 
used for imaging and localization as well as calculation of the radioiodine thyroid uptake 
ratio (Bonnema et al, 2012).  It has physical half-life of eight days and effective half-life of 
six days (Cepkova et al, 2014). Remnant RAI ablation successful rate is quite high and 
about 70% of loco-regional lymphadenopathies and pulmonary micrometastasis are cured 
(Haugen B.R. et al, 2015; F. Pacini et al, 2012). 
 Within 1 hour of Iodine-131 ingestion, iodine will be reduced to iodide in the small 
bowel and will enter blood circulation. The follicular cell of the thyroid traps iodide via 
iodide simporter and then organifies the iodide. Iodide will be concentrated up to 500 times 
greater than plasma level. After that, iodide undergoes oxidization, iodination, coupling and 
is stored in the colloid cells (Ziessman et. al, 2013). RAI-131 emits high energy of β-ray, 
which causes damage of DNA directly, and indirectly by formation of free radical. This 
will result in apoptosis or damage of the residual thyroid tissue with little damage to other 
tissues.   
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 There is no dose limit for Iodine-131 administration by the International Atomic 
Energy Agency (IAEA) and International Commission on Radiological Protection (ICRP). 
In general, the dose of Iodine-131 is 1.1-11.1GBq which is equal to 30-300mCi. The 
maximum permissible dose is limited by the absorbed dose of Iodine-131 to the bone 
marrow and also its retention in the lung. (Ravichandran et al, 2014, Willegaignon et al 
2006). In recent years, DTC treatment has become more conservative with less extensive 
surgery, reduced Iodine-131 usage and with lesser follow up for low and intermediate risk 
patients (Lamartina L. et al, 2018) 
 However, radiation released from Iodine-131 could give early and late 
complications. Early complications include sialadenitis, xerostomia, worsening swelling of 
tumour, radiation thyroiditis and gastritis. On the other hand, late complications include 
chronic sialadenitis and xerostomia, secondary malignancy, radiation cystitis and transient 
infertility (Ziessman et al, 2013). 
 The risks of radiation pneumonitis and lung fibrosis are raised for patients who 
receive multiple Iodine-131 in a short interval or large administered activities of Iodine-131 
in diffuse lung metastasis DTC. Radiation-induced pulmonary fibrosis was reported about 
1-7% in DTC patients with lung metastases after receiving Iodine-131 ablation (Jang E.K, 
et al, 2015). Respiratory complication may be avoided if limiting Iodine-131 with bo dy 
retention at 48hours is less than 80mCi (Cho S.W. et al, 2014).  Pre-treatment with 







1.3 Pulmonary Function Test 
 
 A good pulmonary function could be more important for quality of life in DTC 
patients due to its relatively longer survival rate as compared to other cancers. As to date, 
there is only one study done on changes in serial pulmonary function test before and after 
multiple Iodine-131 ablations in Korea by Jang E.K et al (2015). The study found that 
severe impairment of pulmonary function was observed in 16% of DTC after a median of 3 
Iodine-131 ablations.  A few risk factors affecting the pulmonary function include elderly, 
respiratory symptoms, mild impairment baseline and progressive diseases.  To date, there is 
no local data on assessing pulmonary function test among DTC patients that had treatment 
with radioiodine-131. 
 Pulmonary function tests (PFTs) are a tool to assess the function of the lung, chest 
wall and respiratory muscle. It includes a variety of tests which examine the performance of 
the lungs. It is used to establish the pulmonary function’s baseline, evaluates symptoms, 
detection of pulmonary disease, evaluate pulmonary impairment, operative risk and 
surveillance for occupational-related pulmonary disease.  
 The most basic test is spirometry as it is simple and quick procedure. It measures 
the amount of air in the lungs can hold as well as measures how forcefully one can empty 
air from the lungs. As for that, spirometry is used to screen for disease that affect lung 
volumes and disease that affect the airway. Abnormal pulmonary function can be divided 
into obstructive abnormality or restrictive abnormality (Jang E. K. et al, 2015). For 
example, an obstructive abnormality can be seen in patients with asthma and COPD while 




 Guidelines for performing and interpreting PFT have been published by the 
European Respiratory and American Thoracic Societies (Ranu H. et al, 2011). Pulmonary 
function is measured based on forced expiratory volume in 1 second (FEV1), forced vital 
capacity (FVC) and FEV1/FVC (%).  An obstructive pulmonary function is defined as 
FEV1 is reduced more than FVC, FVC ≥80% and FEV1/FVC <70% and restrictive 
pulmonary function is defined as FVC is reduced, FVC <80% and FEV1/FVC ≥70%. 
(Ranu H. et al, 2011, Jang E. K. et al, 2015).  Flow volume loop is generated from the 
reading when patient performs a maximal inspiratory manoeuvre and followed by a 
maximal expiratory manoeuvre (Ranu H. et al, 2011). This flow volume loop is helpful in 
interpreting PFT.  
 Diffusing capacity of the lungs for carbon monoxide (DLCO) is a test to measures 
the ability of a gas to go from the air sacs into the blood stream. It gives important 
information regarding the integrity of the pulmonary vascular bed and alveolar membrane 
(Ranu H. et al, 2011). The spirometry is to differentiate an obstructive abnormality from a 
restrictive abnormality and DLCO gives a clue as to what disease process within that 
category is present. A low DLCO can be seen in both emphysema and interstitial fibrosis. 
In restrictive pulmonary function, interstitial fibrosis may cause a low DLCO but chest wall 
deformities would not. 
 Baseline and serial pulmonary function tests might be considered for some high risk 
patients during follow up. It may be crucial for tracking pulmonary disease, quantifying 
responses to therapy, and early diagnoses of pulmonary injury after exposure to radiation 





2.0 RATIONALE/BENEFITS OF THE STUDY 
 
This study is conducted to determine the role and significance of the usage of PFT 
in assessing pulmonary function in thyroid cancer patients who receive Iodine-131 ablation. 
It may be crucial for tracking early diagnosis of pulmonary injury after exposure to 
radioiodine. PFT is done to quantitatively measure lung function before and after the 
Iodine-131 ablation. It is also to identify clinical factors associated with impaired 
pulmonary function. By identifying the risk factor, baseline of pulmonary function and 
impairment of pulmonary function detection on serial assessment of an identified patient, 
these could possibly change the management plan and increase the quality of the patients’ 
life. Nevertheless this study is also to establish local data regarding changes in pulmonary 




To evaluate changes in pulmonary function of DTC patients after exposure to first Iodine-









 General Objective 2.2.1
• To identify the changes in PFT of DTC patients post first Iodine-131 ablation 
 
 Specific Objective 2.2.2
• To determine the relationship between PFT and Iodine-131 ablation for DTC 
patients 
• To compare changes in PFT after first Iodine-131 ablation for patients with and 
without lung metastasis 
• To identify significant risk factor affecting PFT in post first Iodine-131 ablation 
 
2.3 Hypothesis Statement 
• Null hypothesis: There is no significant worsening in PFT of DTC patients after 
first Iodine-131 ablation 
• Alternative hypothesis: There is significant worsening in PFT of DTC patients after 






3.1 Study Design, Study Location and Study Period 
	
 A prospective observational study was conducted in Hospital Pulau Pinang 
involving the Nuclear Medicine Department and Chest Clinic, Medical Department from 
the period of September 2016 until August 2018 with patient recruitment from September 
2016 until January 2018.  
 
3.2 Study Sample 
 
 Patients with thyroid cancer who underwent total thyroidectomy and underwent 
RAI ablation in Peninsular Malaysia were the population of reference. Thyroid cancer 
patients who were referred to the Nuclear Medicine Department, Hospital Pulau Pinang for 
RAI ablation were the source population. Hospital Pulau Pinang is a government hospital 
based in the northern part of Peninsular Malaysia. The Nuclear Medicine Department 
receives RAI ablation referrals from the states in the northern region of Peninsular 
Malaysia including Penang, Kedah, Perlis as well as Northern Perak. Patients who came for 
their first Iodine-131 ablation in the Nuclear Medicine Department, Hospital Pulau Pinang 
were the sampling population. The study participants were those who had given consents to 
participate in this study and also fulfilled all the inclusion and exclusion criteria. 





3.3 Inclusion and exclusion Criteria 
  
 Inclusion Criteria 3.3.1
• Adult thyroid cancer patient with age more than 18 years old 
• Patient who underwent total or near total thyroidectomy (including completion 
thyroidectomy) 
• HPE: confirmed DTC  
• Patient who received their first Iodine-131 ablation 
• Patient with/without underlying respiratory disease 
 
 Exclusion Criteria 3.3.2
• Patient who were pregnant or breastfeeding 
• Patients who had received RAI ablation before 
 
3.4 Data Collection 
 
 Patient selection and preparation before Iodine-131 ablation  3.4.1
 
All DTC patients who were referred to Nuclear Medicine, Hospital Pulau Pinang for 
their first Iodine-131 ablation were required elective admission to the ward. Dates for 
admission, explanation and a copy of the leaflet from Nuclear Department regarding the 
instruction and list of preparation for Iodine-131 ablation were given to the patients by the 
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referring team (APPENDIX C). This preparation was to ensure the effectiveness of Iodine-
131 ablation.  
A reminder and further explanation on the preparation were given to the patients via 
phone call a few weeks before treatment. Patients were instructed to withhold Tab. L-
Thyroxine and iodine containing medicines or supplements for 4 weeks prior to admission. 
Patients also were advised to avoid high iodine containing food 2 weeks prior to admission 
such as seafood and sea salt. 
Early in the morning on the day of the admission, all patients were clerked and 
examined to ensure they were in compliance to the preparation. Blood was taken to check 
for stimulated TSH and baseline stimulated serum Tg. The patients were screened by the 
Principal Investigator (PI) and those who fulfilled the inclusion criteria were selected to be 
part of this study. All participants were given counselling and were informed on the 
consents by the PI. Clinical data and written consents were obtained (APPENDIX D and 
E).  
Refer APPENDIX A for study flow chart. 
 
 Baseline Pulmonary Function Test (1st PFT) 3.4.2
 
In the morning, participants were sent to the Chest Clinic, Medical Department, 
Hospital Pulau Pinang after ward admission for their first PFT as a baseline reading.  In the 
afternoon, Iodine-131 (80-150mCi) was given to the participants orally and they were 
warded for 4-5 days in isolation. The low risk group received 80mCi, the intermediate risk 
group with no evidence of metastasis to the lymph node received 100mCi, while the 
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intermediate risk group with evidence of metastasis to lymph node received 120mCi. 
150mCi was given to the high risk group which presented with metastasis.  
Whole body scan (WBS) was performed 4-5 days after Iodine-131 ingestion using 
gamma camera. Images were obtained to detect remnant of thyroid tissue in the neck and 
any distant metastasis. Planar image of whole body were acquired at table rate of 10cm/min 
and spot view of neck were acquired for 480 seconds using gamma camera (Siemen), High 
Energy General purpose (HEGP) collimator and 20% window was set at the peak energy of 
360keV.  
WBS post ablation and CT scan of lung (for positive uptake) is a standard procedure 
(any patient outside of this study would still need to undergo this procedure if necessary). 
Participants’ staging were based on their histopathological examination (HPE) findings, 
radiological imaging (CT scan) and post RAI ablation WBS. Presence of local lymph node 
can be observed via HPE findings and CT scan while mediastinal or distance lymph node 
can be observed by CT scan or / and post Iodine-131 ablation WBS.   
All participants were discharged from the ward after Iodine-131 ablation WBS and 
external dose rate falls below 50µSv/H (Atomic Energy Licensing Act 1984, Act 304).  
 
 Second and Third Pulmonary Function Test (2nd and 3rd PFT) 3.4.3
 
All patients were given follow up appointments in the Nuclear Medicine 
Department for another 3 months (up to 6 months) after first Iodine-131 ablation. Serum Tg 
and thyroid function test were monitored. They were assessed clinically and monitored 
biochemically for any possibility of persistent, progressive or recurrence disease. All the 
	
21	
participants went for second PFT in the Chest Clinic on the same day, prior to clinic follow 
up in the afternoon.  
On the 6th month of follow-up, patients with known metastasis either from CT scan 
or post first Iodine-131 ablation WBS underwent second Iodine-131 ablation. While 
patients without metastasis underwent first diagnostic WBS with low dose Iodine-131 
(5mCi). All participants went for third PFT in the Chest Clinic on the same day and prior to 
Iodine-131 ingestion in the afternoon.  
Any important and relevant clinical parameters were obtained during clinical 
reviews and were documented in the data collection form (APPENDIX F).  
 
 Pulmonary Function Test Procedure 3.4.4
 
Participants were first seated on chairs and were told to breathe normally. They 
were asked to slowly blow out air until the lungs felt empty. Then they should be taking a 
big deep breath to completely fill up their lungs (maximal inspiratory manoeuvre). As soon 
as their lungs felt full, they blew out into the spirometer mouthpiece as hard and fast as they 
could until they felt their lungs were absolutely empty (maximal expiratory effort). They 
were required to repeat all the steps for at least 3 times to be sure the results were 
acceptable and reproducible. This test was conducted by the Medical assistant (MA) in 
charge of the respiratory clinic.  
Several numbers were generated including the FEV1 and FVC. Flow volume 
loop/curve were generated by those numbers. All the readings were recorded, analysed and 
interpreted using winspiroPRO HL7 interface specification Ver 1.0 (March 2012) based on 
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Knudson prediction equation (1983) and American Thoracic Society (ATS) Guideline. The 
results were validated by respiratory physician.  
The PFT machine was calibrated by the MA in charge every other day by using 3 L 
calibration syringe.  
 
FIGURE 3.1: Spirometer  
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 Study Outcome 3.4.5
 
Participants who had worsening in serial PFT at 3 or 6 months after their first Iodine-131 
ablation would demonstrate either one of the outcomes below: 
1. From a baseline of normal PFT to mild or moderate or moderately severe 
abnormal PFT; 
2. From a baseline of mild abnormal PFT to moderate or moderately severe 
abnormal PFT; and 
3. From a baseline of moderate abnormal PFT to moderately severe abnormal PFT. 
 
If there is no worsening in serial PFT, the participants would demonstrate either one of the 
outcomes below: 
1. No changes from a normal baseline PFT and serial PFT 
2. No changes from a mild abnormal PFT and serial PFT; and  
3. No changes from a moderate abnormal PFT and serial PFT.  
 
An abnormal PFT can be divided into restrictive and obstructive.  An obstructive 
pulmonary function is define as an FVC ≥80% and FEV1/FVC <70% and suggestive of 
restrictive pulmonary function if FVC <80% and FEV1/FVC ≥70%. Restrictive and 
obstructive pulmonary function can be further divided into mild, moderate, moderately 
severe, severe and very severe. Grading for obstructive pattern based on FEV1 while 
restrictive pattern based on FVC (Table 3.1) (Pulmonary Function Test in Clinical Practice 
by Ali Altalag, 2009).  
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TABLE 3.1: Severity Grading of Abnormal Pulmonary Function Test 
 
 
3.5 Data Analysis 
 
Statistical analysis were performed using IBM Statistical Package for Social 
Science software version 19. Descriptive results were expressed as frequency (percentage), 
mean ± standard deviation for normal data or median (IQR) for skewed data. Comparison 
between two groups was performed using Chi-square test or Fisher Exact’s when correction 
is needed. The differences between two groups were analysed by using the Mann-Whitney 
test. The differences between serial pulmonary function test results were analysed by using 







Grading FEV1 (obstructive) or FVC (restrictive) 
Mild ≥70% 
Moderate 60-69% 
Moderately severe 50-59% 
Severe 35-49% 
Very severe <35% 
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3.6 Ethics and Disclosure 
 
This study was in accordance with the ethical standards of Malaysian Guideline for 
Good Clinical Practice (National Committee for Clinical Research, 2011) as well as the 
Helsinki Declaration of 1964, revised in 2013 (World Medical Association 2013). This 
study has been approved by the Medical Research Ethics Committee (MREC) of the 
Malaysian Ministry of Health and registered with the National Medical Research Register 
(NMRR-15-2465-28418)(APPENDIX H). This study also has been approved by the 
Jawatankuasa Etika Penyelidikan Manusia (JEPeM) of Universiti Sains Malaysia 
(USM/JEPeM/17100428)(APPENDIX I). 
Written informed consent was obtained from all study participants prior to the 
initiation of the study. Confidentiality was strictly maintained, and data was rendered as 
anonymous except for the purpose of subject identification during statistical analysis. The 








4.1 Demographic Data 
 
A total of 53 participants who were referred for their first Iodine-131 ablation were 
eligible to be recruited based on inclusion and exclusion criteria. However, only 49 
pariticipants were enlisted in this study due to inability of the participants to complete the 
study due to defaulted follow up. 
The median age of the enlisted participants was 42 years old while the youngest was 
18 years old and the oldest was 78 years old. Most of them belong to the age group of 21 to 
40 years old (Figure 4.1). 
 




Based on TNM staging, only nine participants (18%) were more than 55 years old, 
who were under the high-risk group for recurrence. While majority, 40 participants (82%) 
were 55 years old or less and they fell under the lower risk group (Figure 4.2). 
 
 
FIGURE 4.2: Age distribution base on TNM staging 
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